Cancer Drug Resistance Reaches New Heights with 2024 CiteScore™ of 8.3
On June 3, 2024, Elsevier’s Scopus database officially released the 2024 CiteScore™ metrics — Cancer Drug Resistance (CDR), published by OAE Publishing Inc., proudly announces a major milestone: a 2024 CiteScore of 8.3, reaching an all-time high. This marks a notable 25.8% increase from last year’s score of 6.6, underscoring the CDR’s rising academic impact and global recognition.
CiteScore Growth Over the Years:
- 2022: 5.5
- 2023: 6.6
- 2024: 8.3
This steady upward trajectory highlights CDR’s strengthening position as a leading platform for innovative research in cancer drug resistance.
2024 Ranking Highlights:
- #36 out of 275 journals in Pharmacology (Medical) — placing CDR in the top 13% globally (up 30 positions from last year)
- Q2 in Cancer Research — ranked 65th out of 233 journals (top 28%)
These accomplishments reinforce CDR’s mission to publish cutting-edge, peer-reviewed research addressing one of oncology’s most pressing challenges: drug resistance in cancer.
A Note of Appreciation
This success would not have been possible without the collective efforts of our dedicated community:
- To our authors: Thank you for entrusting us with your groundbreaking contributions.
- To our Editorial Board: Your dedication to excellence and integrity continues to raise the bar.
- To our Junior Editorial Board: Your innovative insights help shape the future of resistance research.
- To our reviewers: Your rigorous evaluations uphold the integrity and quality of our publications.
- To our readers: Your continued engagement fuels the impact of the journal.
This achievement is both a proud reflection of past progress and a powerful motivator for what lies ahead. Together, we look forward to further advancing the field and contributing meaningfully to the global fight against cancer drug resistance.
Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance
